However, a promising approach yet to be proven clinically is based on engineering CAR-T cells to produce IL-12 and IL-18 and converting the environment to an acute inflammatory state, enhancing T-cell activation and tumour control, especially in macrophage-rich tumours like SCLC. The gene discussed is IL18; the disease is neoplasm.